Biofrontera (BFRI) Change in Account Payables (2024 - 2025)

Biofrontera's (BFRI) quarterly Change in Account Payables came in at -$2.3 million in Q4 2025, down 237.63% year-on-year from $1.7 million in Q4 2024, and down 267.46% quarter-over-quarter from -$630000.0 in Q3 2025.

Biofrontera (BFRI) Change in Account Payables (2024 - 2025) Analysis & Trends

Biofrontera's Change in Account Payables history runs 2 years deep, the most recent figure standing at -$2.3 million for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 237.63% year-over-year to -$2.3 million in Q4 2025; TTM through Dec 2025 was -$533000.0, a 50.14% decrease from a year earlier, with the FY2025 full-year figure at -$533000.0, down 50.14% from the prior year.
  • Change in Account Payables retreated to -$2.3 million in Q4 2025 per BFRI's latest filing, from -$630000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.7 million in Q4 2024 and bottomed at -$2.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 62.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 30.60 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 32.70 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Biofrontera 12.70 Mn 6.29 Mn 14.09 Mn -2.32 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -2.32 Mn
Dec 31, 2025 -2.32 Mn
Sep 30, 2025 -630,000.00
Sep 30, 2025 -630,000.00
Jun 30, 2025 968,000.00
Jun 30, 2025 968,000.00
Mar 31, 2025 1.44 Mn
Mar 31, 2025 1.44 Mn
Dec 31, 2024 1.68 Mn
Dec 31, 2024 1.68 Mn
Sep 30, 2024 1.40 Mn
Sep 30, 2024 1.40 Mn
Jun 30, 2024 -1.61 Mn
Jun 30, 2024 -1.61 Mn
Mar 31, 2024 -1.83 Mn
Mar 31, 2024 -1.83 Mn